Anuradha Gopalan
Overview
Explore the profile of Anuradha Gopalan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
9769
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li F, Dai P, Shi H, Zhang Y, He J, Gopalan A, et al.
Cell Res
. 2025 Jan;
35(1):59-71.
PMID: 39743630
Epigenetic regulation profoundly influences the fate of cancer cells and their capacity to switch between lineages by modulating essential gene expression, thereby shaping tumor heterogeneity and therapy response. In castration-resistant...
2.
Romero R, Chu T, Gonzalez Robles T, Smith P, Xie Y, Kaur H, et al.
Nat Cancer
. 2024 Oct;
5(11):1641-1659.
PMID: 39394434
Lineage plasticity is a hallmark of cancer progression that impacts therapy outcomes, yet the mechanisms mediating this process remain unclear. Here, we introduce a versatile in vivo platform to interrogate...
3.
Samueli B, Al-Ahmadie H, Chen Y, Gopalan A, Sarungbam J, Tickoo S, et al.
Mod Pathol
. 2024 Sep;
38(1):100616.
PMID: 39326497
Gain-of-function isocitrate dehydrogenase (IDH) mutations are pathogenically significant in many tumor types and are actionable in cholangiocarcinoma, low-grade glioma, and acute myeloid leukemia. Rare IDH mutations have been described in...
4.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(28):e2322203121.
PMID: 38968122
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
5.
Akbulut D, Whiting K, Teo M, Tallman J, Gokturk Ozcan G, Basar M, et al.
Mod Pathol
. 2024 Jul;
37(10):100557.
PMID: 38964503
Small cell carcinomas (SMC) of the lung are now molecularly classified based on the expression of transcriptional regulators (NEUROD1, ASCL1, POU2F3, and YAP1) and DLL3, which has emerged as an...
6.
Lenis A, Ravichandran V, Brown S, Alam S, Katims A, Truong H, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3894-3903.
PMID: 38949888
Purpose: Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and response to immune...
7.
Wang L, Vasudevaraja V, Tran I, Sukhadia P, Reuter V, Abu-Rustum N, et al.
Int J Gynecol Pathol
. 2024 Jun;
44(1):88-93.
PMID: 38833720
Androgen receptor splicing variant 7 (AR-V7) is a truncated variant of the AR mRNA that may be a predictive biomarker for AR-targeted therapy. AR-V7 has been described in prostate, breast,...
8.
Romero R, Chu T, Gonzalez-Robles T, Smith P, Xie Y, Kaur H, et al.
bioRxiv
. 2024 Apr;
PMID: 38645223
Lineage plasticity is a recognized hallmark of cancer progression that can shape therapy outcomes. The underlying cellular and molecular mechanisms mediating lineage plasticity remain poorly understood. Here, we describe a...
9.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv
. 2024 Apr;
PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
10.
Feng W, Ladewig E, Salsabeel N, Zhao H, Lee Y, Gopalan A, et al.
bioRxiv
. 2024 Apr;
PMID: 38585869
To gain insight into how ERG translocations cause prostate cancer, we performed single cell transcriptional profiling of an autochthonous mouse model at an early stage of disease initiation. Despite broad...